Cingulate_Logo_400x400_twitter.jpg
Cingulate Benzinga All Live Access Appearance Rescheduled for December 16
December 01, 2022 14:00 ET | Cingulate Inc.
KANSAS CITY, Kan., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate_Logo_400x400_twitter.jpg
Cingulate to Participate in Benzinga All Live Access Event
November 30, 2022 15:00 ET | Cingulate Inc.
KANSAS CITY, Kan., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Consolidated Balance Sheet Data
Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
November 14, 2022 06:45 ET | Cingulate Inc.
Phase 3 Trial Initiation for Lead ADHD Candidate CTx-1301 in December 2022 Executed Manufacturing Agreement with Societal CDMO 2022 Psych Congress Presentation Demonstrated Ability of Anxiety...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD
November 01, 2022 09:02 ET | Cingulate Inc.
KANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update
October 24, 2022 16:45 ET | Cingulate Inc.
KANSAS CITY, Kan., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate_Logo_400x400_twitter.jpg
Cingulate to Present at LD Micro Investor Conference
October 20, 2022 14:20 ET | Cingulate Inc.
KANSAS CITY, Kan., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103
September 19, 2022 06:45 ET | Cingulate Inc.
Data Demonstrated Ability of CTx-2103 to Deliver a Single Administration of Triple-Release Buspirone – Setting the Stage for Future Trials Employing Cingulate’s Precision Timed Release™ (PTR™)...
Cingulate_Logo_400x400_twitter.jpg
Cingulate to Participate in Benzinga All Live Access Event
August 15, 2022 18:34 ET | Cingulate Inc.
KANSAS CITY, Kan., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
August 11, 2022 06:45 ET | Cingulate Inc.
$5 Million of Non-Dilutive FinancingVeteran Biotech Executive Appointed to Board KANSAS CITY, Kan., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage...
Cingulate_Logo_400x400_twitter.jpg
Kansas City Business Journal Names Cingulate’s Louis G. Van Horn a 2022 Chief Financial Officer of the Year
July 25, 2022 13:45 ET | Cingulate Inc.
KANSAS CITY, Kan., July 25, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...